PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Thomas J Walsh Selected Research
Infection
06/2008
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
03/2008
Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and therapy.
02/2007
Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
12/2006
Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection.
02/2006
Immunotherapy for fungal infections.
02/2006
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
01/2006
Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
08/2005
Posaconazole: clinical pharmacology and potential for management of fungal infections.
06/2005
Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection.
02/2005
Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics.
02/2005
Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
11/2004
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
08/2004
Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children.
05/2003
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
02/2003
Candida tropicalis in a neonatal intensive care unit: epidemiologic and molecular analysis of an outbreak of infection with an uncommon neonatal pathogen.
03/2002
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Articles by Research Topic
Disease
16
Aspergillosis
09/2008 - 01/2002
16
Infection
06/2008 - 03/2002
15
Candidiasis (Moniliasis)
10/2007 - 05/2002
8
Neutropenia
02/2007 - 01/2002
2
Neoplasms (Cancer)
06/2008 - 02/2007
2
Chronic Granulomatous Disease
02/2006 - 06/2005
2
Fever (Fevers)
09/2004 - 01/2002
1
Mycoses (Diseases, Fungus)
06/2008
1
Abdominal Pain (Pain, Abdominal)
03/2008
1
Meningoencephalitis
01/2008
1
Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/2007
1
Kidney Failure (Renal Failure)
07/2005
1
Meningitis
06/2003
1
Leukemia
04/2003
Drug/Important Bio-Agent (IBA)
7
galactomannan
IBA
09/2008 - 01/2002
6
caspofungin (Cancidas)
FDA Link
09/2007 - 01/2002
5
micafungin (FK463)
FDA Link
01/2008 - 06/2002
5
Fluconazole (Zonal)
FDA Link
Generic
06/2007 - 09/2004
5
voriconazole (Vfend)
FDA Link
04/2007 - 01/2002
5
posaconazole
FDA Link
01/2007 - 06/2005
4
Amphotericin B (Amphotericin)
FDA Link
Generic
10/2007 - 07/2003
3
anidulafungin
FDA Link
06/2007 - 09/2004
3
liposomal amphotericin B
FDA Link
04/2007 - 01/2002
2
Antifungal Agents
IBA
02/2007 - 01/2007
2
PLD118
IBA
05/2005 - 10/2004
2
Isoleucine-tRNA Ligase
IBA
05/2005 - 10/2004
1
Sodium Glutamate (Accent)
IBA
06/2008
1
Hormones
IBA
03/2008
1
Triad resin
IBA
03/2008
1
Flucytosine (Ancobon)
FDA Link
10/2007
1
Itraconazole (Sporanox)
FDA Link
Generic
01/2007
1
Antigens
IBA
01/2007
1
DNA (Deoxyribonucleic Acid)
IBA
01/2006
1
Interferon-gamma (Interferon, gamma)
IBA
08/2004
1
Colony-Stimulating Factors (Colony Stimulating Factor)
IBA
08/2004
1
ER 30346 (ravuconazole)
IBA
04/2004
1
Lysine (L-Lysine)
FDA Link
04/2004
1
Interleukin-4 (Interleukin 4)
IBA
04/2003
1
Echinocandins
IBA
12/2002
1
cyclodextrin itraconazole
IBA
08/2002
Therapy/Procedure
2
Hematopoietic Stem Cell Transplantation
03/2008 - 11/2004
2
Transplantation (Transplant Recipients)
02/2007 - 02/2005
2
Salvage Therapy
12/2006 - 06/2005
1
Immunotherapy
02/2006
1
Renal Dialysis (Hemodialysis)
07/2005
1
Neonatal Intensive Care
02/2003
1
Highly Active Antiretroviral Therapy (HAART)
05/2002